American Vietnamese Biotech

American Vietnamese Biotech Current Assets

The Current Assets of American Vietnamese Biotech (AMV.VN) as of Oct 24, 2026 is 951.89 B VND. In the previous year, Current Assets was 1.58 T VND — a change of -39.83% (lower).

Current Assets

951.89 BVND

YoY

-39.83%

Last updated:

Current Assets of American Vietnamese Biotech is 2024 951.89 B VND. Current Assets of American Vietnamese Biotech was 2023 1.58 T VND. It decreases by -39.83% lower compared to the previous year.

The American Vietnamese Biotech Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2017
382.35 B VND
Jan 1, 2018
344.66 B VND
Jan 1, 2019
152.74 B VND
Jan 1, 2020
358.99 B VND
Jan 1, 2021
1.01 T VND
Jan 1, 2022
1.48 T VND
Jan 1, 2023
1.58 T VND
Jan 1, 2024
951.89 B VND
The American Vietnamese Biotech Current Assets history
YEARCurrent AssetsYoY
951.89 BVND-39.83%
1.58 TVND+6.61%
1.48 TVND+47.52%
1.01 TVND+180.22%
358.99 BVND+135.03%
152.74 BVND-55.68%
344.66 BVND-9.86%
382.35 BVND+3,541.19%
10.50 BVND+33.74%
7.85 BVND-10.64%
8.79 BVND-7.08%
9.46 BVND+45.32%
6.51 BVND-37.51%
10.41 BVND-28.33%
14.53 BVND+50.82%
9.63 BVND-20.71%
12.15 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

American Vietnamese Biotech Stock analysis

What does American Vietnamese Biotech do? American Vietnamese Biotech, Inc. generates revenue through the manufacture and distribution of high-tech medical diagnostics devices and equipment, including rapid diagnostic tests and ELISA kits. The company also produces medicines, vaccines, biological products, and cosmetic, soap, detergent, and cleaning products. Its subsidiary, American - Vietnamese Biology Company Limited, supports these manufacturing operations. The primary buyers are healthcare providers, laboratories, and distributors within the medical and pharmaceutical sectors, as well as consumers purchasing personal care items. The firm's financial investment activities and real estate trading contribute to additional revenue streams, though these are secondary to its core medical product manufacturing. The company's product portfolio targets both B2B segments in healthcare and B2C segments for consumer goods, with a focus on diagnostic tools and personal care solutions. As of 2012, the subsidiary structure remains central to its operational model. American Vietnamese Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about American Vietnamese Biotech stock

Current Assets of American Vietnamese Biotech is 951.89 B VND in 2024.

Current Assets of American Vietnamese Biotech changed from 1.58 T VND to 951.89 B VND, representing a -39.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets American Vietnamese Biotech since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's American Vietnamese Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — American Vietnamese Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — American Vietnamese Biotech